Press Esc to close

Welcome to Money Morning - Only the News You Can Profit From.


This Says Our Favorite Biotech Is Off to the Races

Shares of a promising biotech we recommended back in February 2013 – jumped as much as 27% to a three-month high of $14.20 yesterday after the company said a new cancer drug met its main goal in a midstage clinical trial.

Its shares backtracked a bit as the day progressed but still closed 17.6% higher for the session. These shares have advanced 361% since we first told you about them. The stock has generated a peak gain of 456%, making it one of the 31 recommendations we’ve made to you that have doubled or better since we launched Private Briefing in August 2011. (More on that later…)

  • EU

  • European Finance Minister to Study U.S. Economic Woes From Staff Reports European Union finance ministers open two days of talks today (Monday) to discuss how key U.S. problems as a slowing economy, a super-weak dollar and a huge-and-growing trade deficit will affect the European Union, as well as the rest of the world economy. The falling dollar has made U.S. exports cheaper versus […] Read More...
  • EU Presses for More Energy Control By Jason SimpkinsStaff Writer The European Commission yesterday (Wednesday) introduced a plan calling for a massive restructuring of power grids throughout the continent.  The plan was designed to reduce the region’s vulnerability to the massive energy companies that control the production and transmission of gas and electricity. Currently, large energy companies monopolize energy production and […] Read More...
  • The New Cold War: How Russia Has Turned Its Energy Exports Into Weapons of Diplomacy By Jason Simpkins Last week, (July 20) Chevron Corp. said it would challenge a $290 million back tax claim issued against the Caspian Pipeline Consortium by Russia’s Federal Tax Service. This is yet another attempt by President Vladimir Putin to seize control over all aspects of energy production and transportation within Russia. The Caspian Pipeline […] Read More...